Ivermectin Archives - Amazing Health Advances

Frontline Doctors Develop Protocol to Help Those Injured by COVID Jab

AHA Publisher — Fri, 01 Jul 2022 07:00:16 +0000

Sara Middleton via NaturalHealth365 – Since the late 1980s, the number of petitions filed with the United States National Injury Compensation Program (VICP) seeking compensation for injury or death caused by vaxxes has increased considerably. Last year’s total (2,057) neared the historical peak of 2003 (2,592). It’s yet to be seen how the trend will play out over the next few years. Incredibly, more than half of these petitions have been dismissed, and not all cases that received actual compensation were necessarily able to “prove” that a vax caused the purported injury or illness (although one could safely surmise that the entire VICP process is bogged down with bureaucratic red tape and other behind-closed-doors decisions that protect the best interests of anyone but the vax-injured). Regardless, the point is clear: people have and will continue to be injured by the COVID shots currently authorized for use by the Food and Drug Administration (FDA). Thankfully, while many public health officials, Big Pharma folks, and conventional healthcare providers are sticking their heads in the sand, some frontline doctors are taking a stand – and possibly risking their medical licenses by doing so – to help those who are harmed. No Conspiracy Here: Children and Adults Are Getting Hurt by COVID-19 Shots… But Are They Being Listened to? It’s hard to claim that we’re still in an “emergency” state when it comes to the pandemic (although that certainly isn’t stopping the FDA from authorizing the “emergency” use of the gene-based COVID shots for virtually everyone in the United States older than 6 months old). Meanwhile, data continues to emerge that muddies the water for anyone trying to make informed decisions about these injections. For instance, getting vaxxed seems to increase your risk of getting COVID-19 (a painfully ironic phenomenon known as “negative efficacy,”) which we can infer from the observation that highly vaxxed countries suffer from soaring infection and death rates compared to low vaxxed countries. Additionally, as summarized by Dr. Joseph Mercola in a recent newsletter, official vax safety surveillance data confirm that the mRNA jabs have “caused more harm in 18 months than all other vaxxes on the market, combined, over the past three decades.” And that’s even leaving alone the likelihood that VAERS is not capturing the true incidence of adverse effects from the COVID jabs due to the frustrating reality of adverse event underreporting. Of course, acknowledging that people are suffering serious and sometimes fatal issues because of these heavily propagandized drugs in no way ignores the fact that people have also been suffering because of COVID-19. But bringing to light this issue hopefully will encourage more providers to at least put vax injury on their radar when seeing people suffering from problems such as strokes, fall-related injuries after fainting episodes, heart inflammation, worsening chronic illness, “sudden unexplained deaths,” and more. Because truthfully, if doctors aren’t even considering the possibility that their patients’ suffering could be related to recent jabs due to ignorance or fear of professional repercussions, how would a potential link ever be uncovered? If patients aren’t listened to when they show up to urgent care clinics and emergency rooms, if their concerns are downplayed or ignored, or if their symptoms aren’t reported to VAERS, then how exactly will ongoing safety monitoring of these shots ever be appropriately carried out? Here Are Some Things You Can Do If You Develop Post-Vax Syndrome Following a COVID Shot, According to Frontline Experts The Frontline COVID-19 Critical Care Alliance (FLCCC) is a group of healthcare providers – led by esteemed Pulmonary and Critical Care Specialists Dr. Pierre Kory, M.D., M.P.A., and Dr. Paul E. Marik, M.D., FCCM, FCCP – who have created and shared life-saving, evidence-based protocols for patients throughout the pandemic (protocols that often go against mainstream messaging and are therefore frequently censored). Now, they’ve developed a protocol specifically for people who have suffered illness or injury following a COVID jab. The FLCCC endorses the importance of such a protocol given that “a temporal correlation between a patient receiving a COVID-19 vaccine and beginning or worsening of clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury when the symptoms are unexplained by other concurrent causes.” If you’re curious, here are some “first-line” treatments from the FLCCC Alliance’s “I-RECOVER POST-VACCINE TREATMENT PROTOCOL” (the protocol includes many more treatments as well, including several non-pharmacological options): Intermittent daily fasting Vitamin C, D, and K2 Magnesium Melatonin Quercetin Nigella Sava Omega-3 fatty acids Ivermectin Aspirin Readers note: the FLCCC encourages patients to consult with a healthcare provider before starting any new treatment protocol, and that any treatment protocol should be individualized based on each patient’s needs. Keep this in mind as you search for a healthcare provider you can trust with your family’s health and wellbeing. Sources for this article include: Statista.com Rumble.com COVID19criticalcare.com Mercola.com Mercola.com To read the original article click here.

The post Frontline Doctors Develop Protocol to Help Those Injured by COVID Jab appeared first on Amazing Health Advances.

Anti-Malaria Drug Fights Cancer, 9 Peer-Reviewed Studies Suggest

AHA Publisher — Wed, 11 May 2022 07:00:55 +0000

Sara Middleton via NaturalHealth365 – Can a cheap drug used to fight malaria have a protective effect against cancer? As it turns out, data from at least nine peer-reviewed studies say yes. The drug in question? None other than ivermectin has gained much notoriety thanks to the COVID-19 pandemic and concerns about widespread suppression of early treatments for the viral illness. Nobel Prize-Winning Drug, Considered One of the World’s “Essential Medicines” by the World Health Organization, Also Shows Promise in the Fight Against Cancer Ivermectin certainly became a household name during the pandemic, thanks largely to early laboratory research showing that the drug could inhibit the replication of SARS-CoV-2. While these findings – featured in a June 2020 study by Caly et al. published in Antiviral Research – involved Petri dishes only, the researchers’ work was corroborated with plenty of real-world clinical evidence, as doctors worldwide began treating their COVID-19 positive patients with ivermectin. The treatment appeared to be a great success, at least before health officials began prohibiting or otherwise disincentivizing these doctors from prescribing the drug. However, the apparent success of ivermectin in treating a viral illness like COVID-19 isn’t unusual when we consider the history of the drug. The drug first made the World Health Organization’s List of Essential Medicines in 1987 for its effectiveness against onchocerciasis or river blindness. Ivermectin also has uses against other parasitic diseases, including lymphatic filariasis, strongyloidiasis, trichuriasis, ascariasis, hookworm diseases, scabies, and ancylostomiasis. (Scientists Satoshi Omura and William Campbell were jointly awarded the Nobel Prize in Physiology or Medicine in 2015 for their work in using ivermectin to treat roundworms.) Research – including a study published in the April 2020 edition of The Lancet Infectious Diseases – also finds that ivermectin appears to have anti-malarial benefits. But the benefits don’t stop there. Rounded up nicely in an article published on April 15, 2022, on the website Cancer.news, at least nine peer-reviewed studies show that ivermectin may be able to fight off cancer cells. Among the studies is a 2017 paper from Biochemical and Biophysical Research Communications, which found that ivermectin could suppress kidney tumor growth while concurrently offering a protective effect on healthy kidney cells. In the Fight Against Cancer, Will Affordable Drug Options Remain Available? A growing body of research shows early support for ivermectin in the treatment of a wide variety of cancers, including kidney, breast, intestinal, lung, colorectal, esophageal, and ovarian cancers. Experts agree that ivermectin appears to have a generally good safety profile. However, as with any drug, ivermectin does have a risk of side effects, including dizziness, vomiting, stomach pain, bloating, nausea, vomiting, loss of appetite, weakness, fatigue, uncontrollable shaking, and chest discomfort. The drug’s package insert also warns against the use of ivermectin during pregnancy (Pregnancy Category C), in part because there are “no adequate and well-controlled studies in pregnant women” (nor in pediatric kids weighing less than 15kg, for that matter). The drug is also excreted in breastmilk. Contraindications notwithstanding, it remains to be seen whether the medical and scientific communities will further study this compound for its use against cancer. Then again, the skeptics among us will say that the drug is incredibly inexpensive compared to other conventional cancer treatments … so why would conventional healthcare providers pass on the opportunity to drive profits with pricier care? Sources for this article include: NIH.gov FDA.gov Cancer.news NIH.gov Medlineplus.gov Essentialmeds.org NIH.gov USAtoday.com To read the original article click here.

The post Anti-Malaria Drug Fights Cancer, 9 Peer-Reviewed Studies Suggest appeared first on Amazing Health Advances.

Nebraska AG Allows Ivermectin and HCQ Prescriptions as Off-Label Medicines to Fight COVID

AHA Publisher — Wed, 20 Oct 2021 07:00:31 +0000

Steve Warren via CBN News – Nebraska’s attorney general has said he will not discipline or prosecute physicians who prescribe controversial, off-label drugs in order to treat and prevent COVID-19 infections if they have patient consent. KETV reported Attorney General Doug Peterson issued his 48-page opinion Friday after receiving a question from Nebraska Department of Health and Human Services CEO Dannette Smith. She asked if doctors could face discipline or legal action under Nebraska’s Uniform Credential Act (UCA) if they prescribed medications like Ivermectin and Hydroxychloroquine to fight COVID-19 in their patients. “After receiving your question and conducting our investigation, we have found significant controversy and suspect information about potential COVID-19 treatment,” Peterson wrote. He also cited numerous medical journals’ articles and case studies. “We emphasize… our office is not recommending any specific treatments for COVID-19. That is not our role,” the attorney general continued. “Rather, we address only the off-label early treatment options discussed in this opinion and conclude that the available evidence suggests they might work for some people,” Peterson wrote. “Allowing physicians to consider these early treatments will free them to evaluate additional tools that could save lives, keep patients out of the hospital, and provide relief for our already strained health care system.” The FDA has cautioned against using hydroxychloroquine (HCQ) to treat COVID. Former President Trump took HCQ early in the pandemic to prevent a COVID-19 infection, then he stopped using it in May of 2020. Other famous people said the drug worked for them. Actor Tom Hanks and his wife Rita Wilson said HCQ was useful in their recovery from the coronavirus. Actor Daniel Dae Kim (Lost & Hawaii Five-0) claimed HCQ was the “secret weapon” that helped in his recovery from the disease. Last year, Pastor A.R. Bernard of the Christian Cultural Center in Brooklyn, NY, talked about his harrowing bout with COVID-19 and how the drug cocktail with hydroxychloroquine and the antibiotic azithromycin saved his life. Families Filing Lawsuits Against Hospitals, Seeking Alternative COVID Treatments for Loved Ones At least two dozen lawsuits have been filed around the U.S., many in recent weeks, by people seeking to force hospitals to give their COVID-stricken loved ones ivermectin, a drug for parasites that has been promoted as a treatment despite a lack of conclusive evidence that it helps people with the virus. Interest in the drug started rising toward the end of last year and the beginning of this one, when studies – some later withdrawn, in other countries – seemed to suggest ivermectin had some potential in the fight against COVID-19. But some medical experts suggest having a court step in is not the way to practice medicine. “The way medicine works is, they are the experts, the doctors and… the hospitals,” Arthur Caplan, professor of bioethics at New York University’s Grossman School of Medicine told the Associated Press. “When you go there, you’re not going to a restaurant. You don’t order your own treatments.” “You can’t have a medical field that’s subjected to having to practice according to patient demand backed up by court orders. That is positively horrible medicine,” Caplan said. Ralph Lorigo doesn’t see it that way. The attorney from Buffalo, New York, filed his first of several ivermectin lawsuits in January after being approached by the family of an 80-year-old woman who was in the hospital on a ventilator. His second case was later that month, for a hospitalized 65-year-old woman. In both cases, judges ordered hospitals to allow the women to take ivermectin as their families wanted. Both women survived their hospitalizations, according to the AP. Lorigo, who has taken on numerous cases since is adamant that ivermectin works. Health experts and federal agencies say that any evidence of it being effective against COVID-19 is slim and more research needs to be done. Studies are currently underway. Israeli Clinical Trials Show Positive Results with Ivermectin As CBN News reported earlier this month, a top Israeli doctor was asked by Israel’s government to research treatments for COVID. His studies indicated positive results with ivermectin in clinical trials. Dr. Eli Schwartz, M.D. is the founder of the Center for Travel Medicine and Tropical Diseases at the Sheba Medical Center in Israel. It’s considered one of the world’s top hospitals. Dr. Schwartz is also a professor at Sackler Faculty of Medicine, Tel Aviv University. For decades, Schwartz has traveled the world fighting outbreaks like Dengue Fever and Ebola. At the beginning of the pandemic and months before any vaccine was available, Israel’s Defense Ministry assigned Schwartz to find a medical solution for COVID-19. “Since Ivermectin is one of the drugs that we are using in daily life in the Tropical Institute, I knew it. I know the safety profile of it. And since there was some hints of in-vitro studies, which show the efficacy against specifically, even against COVID-19, we decided to go for it,” he said. That meant putting the drug through a clinical trial that lasted 10 months. “Our study, which was done here, it’s a randomized controlled trial, double-blind. It’s really, I would say, this is the best method that you are doing studies. And our conclusion is that it really has antiviral activities,” Schwartz told CBN News. From his international experience in the field, Schwartz knew Ivermectin targeted parasites. Since its development in 1987, nearly 4 billion doses with few side effects and at low cost have protected millions of people from insidious parasitical diseases like River Blindness and Elephantiasis. That success won its developers the Nobel Prize for medicine in 2015. Schwartz’s study made headlines in Israel when his trial showed Ivermectin to also be anti-viral. “This is the first drug to show antiviral activity,” the doctor explained. “And then, I think, there’s a good reason to continue with a much more thorough investigation to see, for example, whether people who are at high risk, may not deteriorate to be hospitalized, to be mechanically ventilated, or to death.” Schwartz’s clinical study found that by day four, 86% of his patients who took ivermectin recovered. By day six, 94% recovered. “The bottom line is… Ivermectin decreased faster the viral load, and also sterilized the culture much better compared to the placebo,” he noted. Schwartz explained to CBN News this means Ivermectin killed the virus and his patients became non-infectious. He said this development could save lives and reduce quarantines by days. “It’s a huge change in life. It’s a huge change for the patient. It’s a huge change for his family. And from the economical point of view, it’s a dramatic change. You know, it’s how much money you can save for the economy of the country if you can shorten the isolation time,” he said. Use Not Accepted by Global Heath Professionals But ivermectin is not accepted by the global health establishment. A major FDA concern is that a number of people have tried to self-medicate using a form of the drug intended for livestock. “Don’t do it. There’s no evidence whatsoever that it works and it could potentially have toxicity…with people who have gone to poison control centers because they’ve taken the drug at a ridiculous dose and wind up getting sick,” said Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases. The World Health Organization advises “that Ivermectin only be used be used to treat COVID-19 within clinical trials.” The National Institutes of Health said, “Ivermectin is not approved by the FDA for the treatment of any viral infection” and that “well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.” For studies to be accepted by the broader medical community, it must be peer-reviewed and published in a medical journal. That’s where Prof. Schwartz hit a roadblock. Several journals turned him down, but one is currently reviewing his study. Schwartz added that while many health agencies want better studies, no large-scale trials on ivermectin happened until Oxford University began one in June of this year. “I mean, it took them 18 months from the beginning of the pandemic to try to do it. I mean, people dying all over the world. And you have drug under your hand and you have to wait so long until you get any conduction of a good study,” he said. ‘We Are in the Arms of Pharma, and the Pharma Is Looking for New Drugs’ Now, the pharmaceutical company Merck, which developed ivermectin, and Pfizer are in a race to produce an oral anti-viral drug for COVID that some believe is what ivermectin could do already. “In my view, the whole story of Ivermectin is much beyond Ivermectin. It’s even beyond the corona. The problem is that we are in the arms of the pharma and the pharma is looking for new drugs. And, therefore, all old drugs which might be with a good potential to use it for whatever you’re looking for, there’s not any parents to push for it,” Schwartz claimed. Prof. Schwartz advocates the use of ivermectin but also believes in the vaccine. “Most of the world, still vaccine is not available. So, if we have a medication that can try to reduce the magnitude of the pandemic in the meantime, that’s absolutely needed, but when, if I have to compare the vaccine and Ivermectin for prevention, no doubt the vaccine. This is the solution, the international solution,” he said. Schwartz hopes more research will prove the drug can help fight the pandemic and that it will eventually be allowed to treat patients on a widespread basis and not just within clinical trials. To read the original article click here.

The post Nebraska AG Allows Ivermectin and HCQ Prescriptions as Off-Label Medicines to Fight COVID appeared first on Amazing Health Advances.

Top Israeli Doctor Says Ivermectin Could Help Treat COVID, Urges More Research

AHA Publisher — Tue, 05 Oct 2021 07:00:32 +0000

Chris Mitchell via CBN News – JERUSALEM, Israel – In the battle against COVID-19, most of the world has turned to vaccines as the main line of defense. Still, a number of doctors and hospitals are looking for other options that could potentially play a role in defeating this global pandemic. Several treatments have seen success in treating the disease, such as Regeneron and Remdesevir. The drug Ivermectin also continues to generate interest. While the FDA and other organizations advise against it, one Israeli doctor is reporting positive results in clinical trials. Professor Eli Schwartz is with the Sheba Medical Center in Israel, considered one of the world’s top hospitals. For decades, Prof. Schwartz has traveled the world fighting outbreaks like Dengue Fever and Ebola. He also began the Travel Medicine and Tropical Disease Institute at Sheba. At the beginning of the pandemic and months before any vaccine, Israel’s Defense Ministry assigned Schwartz to find a medical solution for COVID-19. Professor Eli Schwartz. Photo: CBN News “Since Ivermectin is one of the drugs that we are using in daily life in the Tropical Institute, I knew it. I know the safety profile of it. And since there was some hints of in-vitro studies, which show the efficacy against specifically, even against COVID-19, we decided to go for it.” That meant putting the drug through a clinical trial that lasted ten months. “Our study, which was done here, it’s a randomized controlled trial, double-blind. It’s really, I would say, this is the best method that you are doing studies. And our conclusion is that it really has antiviral activities,” Shwartz told CBN News. From his international experience in the field, Schwartz knew Ivermectin targeted parasites. Since its development in 1987, nearly 4 billion doses with few side effects and at low cost have protected millions of people from insidious parasitical diseases like River Blindness and Elephantiasis. That success won its developers the Nobel Prize for medicine in 2015. Schwartz’s study made headlines in Israel when his trial showed Ivermectin to also be anti-viral. “This is the first drug to show antiviral activity. And then, I think, there’s a good reason to continue with a much more thorough investigation to see, for example, whether people who are at high risk, may not deteriorate to be hospitalized, to be mechanically ventilated, or to death.” Schwartz’s clinical study found that by day four, 86% of his patients who took ivermectin recovered. By day six, 94% recovered. “The bottom line is that … Ivermectin decreased faster the viral load, and also sterilized the culture much better compared to the placebo,” he said. Schwartz explained to CBN News this means Ivermectin killed the virus and his patients were non-infectious. Schwartz says this could save lives and reduce quarantines by days. “It’s a huge change in life. It’s a huge change for the patient. It’s a huge change for his family. And from the economical point of view, it’s a dramatic change. You know, it’s how much money you can save for the economy of the country, if you can shorten the isolation time,” he said. But ivermectin is not accepted by the global health establishment. A major FDA concern is that a number of people have tried to self-medicate using a form of the drug intended for livestock. “Don’t do it. There’s no evidence whatsoever that it works and it could potentially have toxicity, as you just mentioned, with people who have gone to poison control centers because they’ve taken the drug at a ridiculous dose and wind up getting sick,” said Dr. Anthony Fauci. The World Health Organization advises “that Ivermectin only be used be used to treat COVID-19 within clinical trials.” The National Institutes of Health says, “Ivermectin is not approved by the FDA for the treatment of any viral infection” and that “well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.” For studies to be accepted by the broader medical community, it must be peer-reviewed and published in a medical journal. That’s where Prof. Schwartz hit a roadblock. Several journals turned him down, but one is currently reviewing his study. “It’s something really very odd. I mean, in my career, I published, I think at least 300 papers and chapters, and I never heard the story that they have with Ivermectin. I think that this kind of international campaign, anti-Ivermectin; same that we have anti-vax, anti-vaccine, we have anti-Ivermectin. I don’t understand,” said Schwartz. Schwartz added that while many health agencies want better studies, no large-scale trials on ivermectin happened until Oxford University began one in June of this year. “I mean, it took them 18 months from the beginning of the pandemic to try to do it. I mean, people dying all over the world. And you have drug under your hand and you have to wait so long until you get any conduction of a good study,” he said. Now, the pharmaceutical company Merck, which developed Ivermectin, and Pfizer are in a race to produce an oral anti-viral drug for COVID that some believe is what Ivermectin could do already. “In my view, the whole story of Ivermectin is much beyond Ivermectin. It’s even beyond the corona. The problem is that we are in the arms of the pharma and the pharma is looking for new drugs. And, therefore, all old drugs which might be with a good potential to use it for whatever you’re looking for, there’s not any parents to push for it,” Schwartz claimed. Prof. Schwartz advocates the use of Ivermectin but also believes in the vaccine. “Most of the world, still vaccine is not available. So, if we have a medication that can try to reduce the magnitude of the pandemic in the meantime, that’s absolutely needed, but when, if I have to compare the vaccine and Ivermectin for prevention, no doubt the vaccine. This is the solution, the international solution,” he said. Schwartz hopes more research will prove the drug can help fight this pandemic and that it will eventually be allowed to treat patients on a widespread basis and not just within clinical trials. To read the original article click here.

The post Top Israeli Doctor Says Ivermectin Could Help Treat COVID, Urges More Research appeared first on Amazing Health Advances.

Israeli Scientist Says COVID-19 Could Be Treated for Under $1/day

AHA Publisher — Mon, 30 Aug 2021 07:00:00 +0000

Maayan Jaffe-Hoffman viaThe Jerusalem Post– Ivermectin, a drug used to fight parasites in third-world countries, could help reduce the length of infection for people who contract coronavirus for less than a $1 a day, according to recent research by Sheba Medical Centerin Tel Hashomer. Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba, conducted a randomized, controlled, double-blinded trial from May 15, 2020, through the end of January 2021 to evaluate the effectiveness of ivermectin in reducing viral shedding among nonhospitalized patients with mild to moderate COVID-19. Ivermectin has been approved by the US Food and Drug Administration since 1987. The drug’s discoverers were awarded the 2015 Nobel Prize in medicine for its treatment of onchocerciasis, a disease caused by infection with a parasitic roundworm. Over the years, it has been used for other indications, including scabies and head lice. Moreover, in the last decade, several clinical studies have started to show its antiviral activity against viruses ranging from HIV and the flu to Zika and West Nile. The drug is also extremely economical. A study published in the peer-reviewed American Journal of Therapeutics showed that the cost of ivermectin for other treatments in Bangladesh is around $0.60 to $1.80 for a five-day course. It costs up to $10 a day in Israel, Schwartz said. In Schwartz’s study, some 89 eligible volunteers over the age of 18 who were diagnosed with coronavirus and staying in state-run COVID-19 hotels were divided into two groups: 50% received ivermectin, and 50% received a placebo, according to their weight. They were given the pills for three days in a row, an hour before a meal. The volunteers were tested using a standard nasopharyngeal swab PCR test with the goal of evaluating whether there was a reduction in viral load by the sixth day – the third day after termination of the treatment. They were swabbed every two days. Nearly 72% of volunteers treated with ivermectin tested negative for the virus by day six. In contrast, only 50% of those who received the placebo tested negative. Over the years, it has been used for other indications, including scabies and head lice. Moreover, in the last decade, several clinical studies have started to show its antiviral activity against viruses ranging from HIV and the flu to Zika and West Nile. The drug is also extremely economical. A study published in the peer-reviewed American Journal of Therapeutics showed that the cost of ivermectin for other treatments in Bangladesh is around $0.60 to $1.80 for a five-day course. It costs up to $10 a day in Israel, Schwartz said. In Schwartz’s study, some 89 eligible volunteers over the age of 18 who were diagnosed with coronavirus and staying in state-run COVID-19 hotels were divided into two groups: 50% received ivermectin, and 50% received a placebo, according to their weight. They were given the pills for three days in a row, an hour before a meal. The volunteers were tested using a standard nasopharyngeal swab PCR test with the goal of evaluating whether there was a reduction in viral load by the sixth day – the third day after termination of the treatment. They were swabbed every two days. Nearly 72% of volunteers treated with ivermectin tested negative for the virus by day six. In contrast, only 50% of those who received the placebo tested negative. IN ADDITION, the study looked at culture viability, meaning how infectious the patients were, and found that only 13% of ivermectin patients were infectious after six days, compared with 50% of the placebo group – almost four times as many. “Our study shows first and foremost that ivermectin has antiviral activity,” Schwartz said. “It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact.” The study appeared on the MedRxiv health-research sharing site. It has not yet been peer reviewed. Schwartz said other similar studies – though not all of them conducted to the same double-blind and placebo standards as his – also showed a favorable impact of ivermectin treatment. His study did not prove ivermectin was effective as a prophylactic, meaning that it could prevent disease, he cautioned, nor did it show that it reduces the chances of hospitalization. However, other studies have shown such evidence, he added. For example, the study published earlier this year in the American Journal of Therapeutics highlighted that “a review by the Front Line COVID-19 Critical Care Alliance summarized findings from 27 studies on the effects of ivermectin for the prevention and treatment of COVID-19 infection, concluding that ivermectin ‘demonstrates a strong signal of therapeutic efficacy’ against COVID-19.” “Another recent review found that ivermectin reduced deaths by 75%,” the report said. BUT IVERMECTIN is not without controversy, and hence, despite the high levels of coronavirus worldwide, neither the FDA nor the World Health Organization have been willing to approve it for use in the fight against the virus. Prof. Ya’acov Nahmias, a Hebrew University of Jerusalem researcher, has questioned the safety of the drug. “Ivermectin is a chemical therapeutic agent, and it has significant risks associated with it,” he said in a previous interview. “We should be very cautious about using this type of medication to treat a viral disease that the vast majority of the public is going to recover from even without this treatment.” During Schwartz’s study, there was not any signal of significant side effects among ivermectin users. Only five patients were referred to hospitals, with four of them being in the placebo arm. One ivermectin patient went to the hospital complaining of shortness of breath on the day of recruitment. He continued with the ivermectin treatment and was sent back to the hotel a day later in good condition. The FDA said on its website it “received multiple reports of patients who have required medical support and been hospitalized after self-medicating with ivermectin.” The “FDA has not approved ivermectin for use in treating or preventing COVID-19 in humans,” it said. “Ivermectin tablets are approved at very specific doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an antiviral (a drug for treating viruses). Taking large doses of this drug is dangerous and can cause serious harm.” The World Health Organization has also recommended against using the drug except in clinical trials. IN CONTRAST, Schwartz said he was very disappointed that the WHO did not support any trial to determine whether the drug could be viable. Last month, Oxford University announced a large trial on ivermectin effectiveness. Schwartz said he became interested in exploring ivermectin about a year ago, “when everyone was looking for a new drug” to treat COVID-19, and a lot of effort was being put into evaluating hydroxychloroquine, so he decided to join the effort. “Since ivermectin was on my shelf, since we are using it for tropical diseases, and there were hints it might work, I decided to go for it,” he said. Researchers in other places worldwide began looking into the drug at around the same time. But when they started to see positive results, no one wanted to publish them, Schwartz said. “There is a lot of opposition,” he said. “We tried to publish it, and it was kicked away by three journals. No one even wanted to hear about it. You have to ask how come when the world is suffering.” “This drug will not bring any big economic profits,” and so Big Pharma doesn’t want to deal with it, he said. SOME OF the loudest opposition to ivermectin has come from Merck Co., which manufactured the drug in the 1980s. In a public statement about ivermectin on its website in February, it said: “Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to date, our analysis has identified no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and a concerning lack of safety data in the majority of studies.” But Merck has not launched any studies of its own on ivermectin. “You would think Merck would be happy to hear that ivermectin might be helpful to corona patients and try to study it, but they are most loudly declaring the drug should not be used,” Schwartz said. “A billion people took it. They gave it to them. It’s a real shame.” And not moving forward with ivermectin could potentially extend the time it takes for the world to be able to live alongside the virus, he said. “Developing new medications can take years; therefore, identifying existing drugs that can be re-purposed against COVID-19 [and] that already have an established safety profile through decades of use could play a critical role in suppressing or even ending the SARS-CoV-2 pandemic,” wrote the researchers in the American Journal of Therapeutics. “Using re-purposed medications may be especially important because it could take months, possibly years, for much of the world’s population to get vaccinated, particularly among low- to middle-income populations.” To read the original article click here.

The post Israeli Scientist Says COVID-19 Could Be Treated for Under $1/day appeared first on Amazing Health Advances.

Antiparasitic Drug Ivermectin Kills Coronavirus in 48 Hours

AHA Publisher — Wed, 08 Apr 2020 07:00:16 +0000

Editor’s Note: We published this article to our website and through our email list at the beginning of the COVID-19 Pandemic, in April of 2020 — well before the highly publicized debate over this drug’s effectiveness. It must be noted that the results of this test were done in vitro. Please see the hyperlinks at the end of this article for further studies. Angela Betsaida B. Laguipo, BSN via News-Medical– Around the world, scientists race to develop a vaccine or treatment against the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, a team of researchers has found that a drug already available around the world can kill the coronavirus in a lab setting in just 48 hours. The drug, Ivermectin, an antiparasitic medicine, is an inhibitor of the virus SARS-CoV-2 in-vitro and can effectively cause a reduction in virus at 48 hours in cell cultures. The FDA-approved drug can be used for repurposing to treat patients affected by COVID-19, which has spread to 184 countries and territories. The researchers at Monash University in Melbourne, Australia, have published their study in the journal Antiviral Research, showing how this already widely-used drug may help combat the current global pandemic rippling across continents. Reduced COVID-19 Viral RNA The team worked with the Peter Doherty Institute of Infection and Immunity. They showed that Ivermectin reduced COVID-19 viral RNA present in cell culture by as much as 93 percent after 24 hours and by 99.8 percent after 48 hours, at around a 5,000-fold reduction in coronavirus RNA, hinting that the medicine can potentially eradicate the virus. “”We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours, there was a significant reduction in it,” Dr. Kylie Wagstaff of the Monash Biomedicine Discovery Institute, said. “Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it in humans will be effective – that’s the next step,” Dr. Wagstaff added. The researchers, however, cautioned that the tests performed in the study were in vitro, and human trials are still needed to determine the efficacy and safety of the drug against the coronavirus. Ivermectin has also shown effectiveness in vitro against a wide range of other viruses, such as the influenza virus, Zika virus, and the human immunodeficiency virus (HIV). Repurposing Ivermectin Ivermectin is an approved drug to treat parasitic conditions, such as rosacea, head lice, and scabies. It was developed in 1975 and has been widely used across the globe since the early 1980s. “In times when we’re having a global pandemic, and there isn’t an approved treatment, if we had a compound that was already available around the world, then that might help people sooner. Realistically, it’s going to be a while before a vaccine is broadly available,” Dr. Wagstaff explained. Though the mechanism of action by which Ivermectin works on the coronavirus is still unknown, the drug works on other viruses by stopping them from inhibiting down the host cells’ ability to detect and fight them. Ivermectin, therefore, warrants further investigation for possible benefits in humans. Further trials should be performed to make sure the drug is effective. If it is effective on humans with coronavirus, it can be widely used to treat affected populations since it already went through approval by the U.S. Food and Drug Administration (FDA). Countries Grapple Against COVID-19 Many countries are unprepared for the coming of the coronavirus disease, which has emerged in China in December 2019. Since then, it has spread to most countries across the globe, touching all continents except Antarctica. The United States reports the highest infections, with more than 368,000 people affected by the virus. It has a staggering 10,923 deaths. Italy has the highest number of deaths, with its death toll reaching 16,523, while Spain has more than 136,000 confirmed cases and 13,341 deaths. Canada has more than 16,000 confirmed cases, while Germany, France, and China have more than 103,000, 98,000, and 82,000 cases, respectively. The coronavirus has dramatically affected the United Kingdom and Australia also, with more than 52,000 and more than 5,700 cases, respectively. This article has been modified. To read the original article click here. Further articles to review regarding Ivermectin: The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro Use of Ivermectin in the Treatment of Covid-19: A Pilot Trial Ivermectin Obliterates 97 Percent of Delhi Cases Why Is the FDA Attacking a Safe, Effective Drug?

The post Antiparasitic Drug Ivermectin Kills Coronavirus in 48 Hours appeared first on Amazing Health Advances.